This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Cidofovir parenteral

Updated 2 Feb 2023 | Cytomegalovirus (CMV)


Parenteral formulations of cidofovir.

Drugs List

  • cidofovir 375mg/5ml concentrate for solution for infusion vial
  • Therapeutic Indications


    Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS

    Cytomegalovirus retinitis in adults with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction.



    Induction treatment: 5mg per kg once a week, for two weeks.

    Maintenance treatment: 5mg per kg every two weeks.


    For intravenous infusion only. Must be diluted in 100ml normal saline prior to administration.


    Children under 18 years
    Concomitant medication consider washout period, see prescribing information
    Proteinuria above 99 mg/dl
    Renal impairment - creatinine clearance below 56 ml/minute

    Precautions and Warnings

    Females of childbearing potential
    Patients over 60 years
    Diabetes mellitus
    Hepatic impairment

    Treatment does not prevent risk of transmission of HIV
    Advise ability to drive/operate machinery may be affected by side effects
    Anti-emetics may be required during therapy
    Concurrent probenecid is required to minimise potential nephrotoxicity
    Discontinue potentially nephrotoxic drugs at least 7 days before starting
    Patients must receive 1L of normal saline intravenously prior to each dose
    Treatment should be initiated by doctor experienced in HIV management
    Avoid contact of powder with skin and mucous membranes
    Avoid contact of prepared solution with skin and mucous membranes
    Staff: Not to be handled by pregnant staff
    Use only if the solution is clear and colourless
    Monitor serum creatinine levels and urine protein levels before each dose
    Monitor ophthalmic function
    Perform differential white blood cell count before each dose
    Consider discontinuation if uveitis/iritis occurs
    Suspend and rehydrate if serum creatinine increases by 44micromol/L or more
    Discontinue if renal function deteriorates
    Suspend therapy and rehydrate if proteinuria is equal to or more than 2+
    Male: May cause infertility
    Female: Contraception required during and for 1 month after treatment
    Male: Use barrier contraception during and for 3 months after treatment

    Pregnancy and Lactation


    Cidofovir is contraindicated during pregnancy.

    The manufacturer does not recommend using cidofovir during pregnancy.

    At the time of writing there is limited data regarding the use of cidofovir during pregnancy. Studies in animals have shown some reproductive toxicity. It is not known if cidofovir crosses the placenta, but its low molecular weight suggests a risk of passage to the foetus.


    Cidofovir is contraindicated during breastfeeding.

    The manufacturer recommends discontinuing breastfeeding whilst taking cidofovir.

    There is limited data on the use of cidofovir during breastfeeding. It is not known if cidofovir or its metabolites are excreted in breast milk. Effects on exposed infants are unknown.

    Side Effects

    Acute renal failure
    Cough increased
    Fanconi syndrome
    Hearing disturbances
    Ocular hypotony
    Oral moniliasis
    Pain - generalised
    Renal failure
    Serum creatinine increased


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2020

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Cidofovir Tillomed 75mg/ml concentrate for solution for infusion. Tillomed Laboratories Ltd. Revised October 2017.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.